Metformin Eql

Metformin, the active ingredient in Metformin Eql, is a biguanide presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving blood glucose control.

GNH USA supplies Metformin Eql as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Eql belongs to the biguanide class and is used to manage disorders of glucose metabolism.

- Type 2 diabetes mellitus: improves glycaemic control and reduces HbA1c levels. - Prediabetes (impaired fasting glucose): may be prescribed to lower the risk of progression to type 2 diabetes. - Polycystic ovary syndrome (off‑label): can help improve insulin resistance when used under specialist supervision.

Metformin Eql may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhoea: loose stools, often early in therapy. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient after dosing. - Loss of appetite: reduced desire to eat. - Flatulence: increased gas production.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic failure: marked liver enzyme elevation. - Hypoglycaemia: uncommon when used alone. - Pancreatitis: inflammation of the pancreas. - Persistent vomiting: may lead to dehydration.

Metformin Eql requires careful monitoring in several clinical situations.

- Renal function assessment: avoid use in severe renal impairment (eGFR <30 mL/min/1.73 m²). - Hepatic function monitoring: contraindicated in acute liver disease. - Vitamin B12 surveillance: long‑term therapy may reduce B12 levels. - Elderly patients: start at lower dose and titrate slowly. - Alcohol consumption: limit intake to reduce lactic acidosis risk. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin Eql can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Alcohol: potentiates risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemic symptoms. - Thiazide diuretics: can increase plasma glucose levels. - ACE inhibitors: may affect renal function, requiring closer monitoring.